Clinical Data Abivax slides on phase 3 data in ulcerative colitis PharmaphorumShares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.Immunology & InflammationRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaphorum Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer. Immunology & Inflammation Read full story Post navigation Previous: Deep Science Ventures and MDC partner to accelerate brain treatmentsNext: AbiVax falls as safety worries cloud ‘landmark’ immune drug results Related Stories Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026 Clinical Data New data could widen use of AstraZeneca, Amgen immune disease drug pharminent August 27, 2026